A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Verastem, Inc.
Seagen Inc.
Seagen Inc.
Eli Lilly and Company
Pheon Therapeutics
Kivu Bioscience Inc.
Kestrel Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
Boehringer Ingelheim
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AbbVie
Travera Inc
Eli Lilly and Company
Nammi Therapeutics Inc
National Cancer Institute (NCI)
Bristol-Myers Squibb
National Institutes of Health Clinical Center (CC)
Jazz Pharmaceuticals
Revolution Medicines, Inc.
AstraZeneca
Pfizer
Actuate Therapeutics Inc.
Alterome Therapeutics, Inc.
EMD Serono
AstraZeneca
Memorial Sloan Kettering Cancer Center
City of Hope Medical Center
Institut Paoli-Calmettes
RasCal Therapeutics, Inc.
Frontier Medicines Corporation
Filamon LTD
Origin Sciences
Tomsk National Research Medical Center of the Russian Academy of Sciences
NeoImmuneTech
Hoffmann-La Roche
UMC Utrecht
Aveni Foundation
ViroMissile, Inc.
University of California, Davis
Massachusetts General Hospital
Erasca, Inc.
Sichuan Enray Pharmaceutical Sciences Company
Duke University
A2 Biotherapeutics Inc.
AstraZeneca
Arvinas Inc.
Tasca Therapeutics
Essen Biotech